LOURES, Portugal, July 6, 2015 /PRNewswire/ --
Hovione announced today the installation of a new large scale
spray drying unit in Loures, Portugal. This new state-of-the-art unit is
specifically designed to handle high potency APIs and to use a wide
variety of organic solvent systems. The unit will be
installed in compliance with the most stringent Quality and Safety
Standards. Spray drying is used in a multitude of pharmaceutical
applications and is often the first technique used to enable poorly
soluble oral drugs, to isolate biopharmaceuticals and for the
production of inhalable dry powder formulations.
The new large scale commercial facility will be in full
operation by March 2016, and
Hovione's Senior Management is enthusiastic about the expansion of
its offering and the new possibilities it entails. According to
Dave Hoffman, Vice President of
Sales & Business Development "The new unit has all
state-of-the-art technological developments and, more importantly,
unique features from an accumulated knowledge of more than 10 years
of experience in commercial spray drying."
This additional commercial unit is the first phase of a broad
expansion program designed to increase the scope of offering,
address customer needs and expand capacity.
"We installed this new spray dryer in response to growing
customer demand for the technology. Hovione's leading
position in spray drying is built on the experience of over 200
development programs. Thanks to our Development by Design
approach we can develop a process and scale it up to a commercial
batch size in a matter of weeks using a minimum quantity of API"
said Filipe Gaspar, Vice President
of Research & Development.
The new unit will add additional capacity to the spray drying
facilities at Hovione. Currently, Hovione has spray drying
facilities in Portugal,
Ireland and the U.S. covering all
of the requirements of the pharmaceutical market in terms of scale,
bioburden control and ability to handle highly potent
materials.
About Hovione
Hovione is an international company with over 50 years'
experience in the development and compliant manufacture of Active
Pharmaceutical Ingredients and Drug Product Intermediates. With
four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most
demanding customers, in the most regulated markets. The company
also offers branded pharmaceutical customers services for the
development and compliant manufacture of innovative new drugs, is
able to support highly potent compounds and offers proprietary
product development and licensing opportunities for drug products.
In the inhalation area, Hovione is the only independent company
offering such a broad range of services. Hovione is a member
of Rx-360, EFCG and participates actively in
industry quality improvement initiatives to lead new global
industry standards. http://www.hovione.com
Contact
Isabel Pina
Director of Corporate Communications
Tel.: +35121-982-9362
ipina@hovione.com
SOURCE Hovione